Two Sigma Investments
KPTI icon

Two Sigma Investments’s Karyopharm Therapeutics KPTI Stock Holding History

Two Sigma Investments’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$842K Buy
151,232
+2,439
+2% +$18.6K ﹤0.01% 3390
2025
Q4 		$1.1M Buy
+148,793
New +$910K ﹤0.01% 2850
2025
Q1 		– Sell
-9,186
Closed -$93.2K – 3363
2024
Q4 		$93.2K Buy
9,186
+3,457
+60% +$41.8K ﹤0.01% 2978
2024
Q3 		$71.3K Buy
5,729
+4,805
+520% +$59.7K ﹤0.01% 2934
2024
Q2 		$12K Buy
924
+11
+1% +$182 ﹤0.01% 2957
2024
Q1 		$20.7K Sell
913
-8,572
-90% -$150K ﹤0.01% 2929
2023
Q4 		$123K Buy
+9,485
New +$128K ﹤0.01% 2921
2023
Q3 		– Sell
-23,170
Closed -$622K – 3091
2023
Q2 		$622K Buy
+23,170
New +$998K ﹤0.01% 2224
2023
Q1 		– Sell
-17,687
Closed -$902K – 3090
2022
Q4 		$902K Buy
17,687
+2,465
+16% +$171K ﹤0.01% 1742
2022
Q3 		$1.25M Sell
15,222
-53,028
-78% -$3.96M ﹤0.01% 1364
2022
Q2 		$4.62M Sell
68,250
-6,278
-8% -$576K 0.02% 812
2022
Q1 		$8.24M Buy
74,528
+8,593
+13% +$1.07M 0.02% 682
2021
Q4 		$6.36M Sell
65,935
-7,177
-10% -$715K 0.01% 1057
2021
Q3 		$6.38M Buy
73,112
+16,704
+30% +$1.73M 0.01% 1049
2021
Q2 		$8.73M Sell
56,408
-43,101
-43% -$6.26M 0.02% 886
2021
Q1 		$15.7M Buy
99,509
+96,828
+3,612% +$20.4M 0.04% 520
2020
Q4 		$622K Sell
2,681
-83,162
-97% -$19.3M ﹤0.01% 2345
2020
Q3 		$18.8M Buy
85,843
+70,127
+446% +$17.2M 0.07% 313
2020
Q2 		$4.46M Sell
15,716
-13,459
-46% -$3.98M 0.02% 692
2020
Q1 		$8.41M Sell
29,175
-21,047
-42% -$5.81M 0.07% 308
2019
Q4 		$14.4M Buy
50,222
+48,774
+3,368% +$10.6M 0.04% 477
2019
Q3 		$209K Sell
1,448
-2,679
-65% -$363K ﹤0.01% 3166
2019
Q2 		$371K Sell
4,127
-18,992
-82% -$1.52M ﹤0.01% 2721
2019
Q1 		$2.02M Sell
23,119
-17,625
-43% -$1.95M 0.01% 1411
2018
Q4 		$5.73M Buy
40,744
+14,147
+53% +$2.39M 0.02% 746
2018
Q3 		$6.79M Sell
26,597
-7,057
-21% -$1.95M 0.02% 808
2018
Q2 		$8.58M Buy
33,654
+25,528
+314% +$6.31M 0.03% 731
2018
Q1 		$1.64M Buy
8,126
+6,511
+403% +$1.3M 0.01% 1673
2017
Q4 		$233K Buy
1,615
+702
+77% +$113K ﹤0.01% 2851
2017
Q3 		$150K Buy
+913
New +$131K ﹤0.01% 2623

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Two Sigma Investments's KPTI Position: Q1 2026 in Review

Two Sigma Investments increased its Karyopharm Therapeutics (KPTI) stake by 1.6% in Q1 2026, buying an estimated $18.6K and bringing the position to 151,232 shares worth $842K. The position accounts for ﹤0.01% of the portfolio, ranked #3390.

Two Sigma Investments first reported a position in KPTI in Q3 2017 and has held it in 30 quarters since. The position peaked at $18.8M in Q3 2020. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • Two Sigma Investments held 151,232 shares of Karyopharm Therapeutics worth $842K as of Q1 2026.
  • Two Sigma Investments bought 2,439 Karyopharm Therapeutics shares in Q1 2026, an estimated $18.6K.
  • Karyopharm Therapeutics made up ﹤0.01% of Two Sigma Investments's portfolio in Q1 2026, its #3390 holding.
  • Two Sigma Investments first reported a position in Karyopharm Therapeutics in Q3 2017 and has held it in 30 quarters since.
  • Two Sigma Investments's Karyopharm Therapeutics position peaked at $18.8M in Q3 2020.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.